The drug discovery pipeline for endometriosis is notoriously sparse. For the estimated one in ten women of reproductive age living with the disease, treatment options have largely stalled at hormonal suppression or invasive surgery, with no new therapeutic class approved in the United States in nearly two decades [HealthyWomen, 2025]. It is a condition defined by tissue that behaves like the uterine lining growing outside the uterus, causing chronic pain and infertility, yet research has been hamstrung by a lack of models that accurately mimic the complex human endometrial environment.
Into that gap steps Metri Bio, a Boston-based biotech startup that believes its laboratory-grown 3D human endometrial organoids can change the equation. The company, which spun out of Yale University in 2023, recently closed a $5 million pre-seed round to use its proprietary tissue models to hunt for first-in-class therapeutics [Metri Bio, June 2024]. The bet is that a better biological model will yield better drug candidates, moving beyond symptom management to potentially alter the course of the disease itself.
A scientific foundation built at Yale
Metri Bio's core technology is not a recent invention. It is the product of more than a decade of academic work in the lab of Dr. Hugh Taylor, the company's scientific co-founder and chair of the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine [Pace Ventures, 2025]. Taylor and his team, including academic co-founder Berna Sozen, have published extensively on developing 3D multicellular models of the human endometrium, work that forms the intellectual bedrock of the startup [Fertility and Sterility 2024].
The company's platform aims to recreate the intricate cellular architecture and hormonal responsiveness of endometrial tissue in a dish. This allows researchers to study disease mechanisms and screen potential drug compounds in a context far more relevant to human biology than traditional 2D cell cultures or animal models. For a condition like endometriosis, where the aberrant tissue interacts with a dynamic hormonal milieu and local immune environment, this fidelity is critical.
The team translating science to medicine
Translating academic research into a clinical-stage biotech requires a specific blend of expertise. Metri Bio's leadership reflects that dual mandate.
| Role | Name | Background |
|---|---|---|
| Co-Founder & CEO | Ashley Abel, MBA | 8+ years in life sciences strategy and operations at ZS Associates and Akili Interactive; Yale MBA [Pace Ventures, 2025]. |
| Co-Founder & Scientific Founder | Hugh Taylor, MD | Chair of Ob/Gyn & Reproductive Sciences at Yale; leading academic in endometriosis biology [Pace Ventures, 2025]. |
| Co-Founder & COO | Kathy Potts, PhD | Startup co-founder and scientific leadership consultant with a PhD from the University of Melbourne [LinkedIn, 2026]. |
| Academic Co-Founder & SAB Chair | Berna Sozen, PhD | Assistant Professor at Yale School of Medicine; co-author on foundational organoid research [Femtech Insider, 2025]. |
CEO Ashley Abel, named to the 2026 Forbes 30 Under 30 list in healthcare, brings the operational and strategic lens [Forbes, 2026]. Her background suggests a focus on navigating the complex path from preclinical discovery to partnership or clinical development. The presence of Taylor and Sozen ensures the science remains closely tied to the leading edge of endometrial biology.
The long road of therapeutic development
The $5 million pre-seed round, led by Pillar VC with participation from Pace Ventures and Slocum Management, provides runway for the early, high-risk work of target identification and compound screening [Founder Lodge, Dec 2025]. The company's stated aim is to discover and develop proprietary drugs, advancing them either in-house or through pharmaceutical partnerships [Fundable, 2025]. This places Metri Bio firmly in the traditional biotech model, where years of preclinical work precede any human trials, and success is measured in regulatory milestones, not monthly recurring revenue.
The funding landscape for women's health, and endometriosis specifically, has seen increased interest but remains a fraction of broader therapeutic areas. Investors like Pillar VC are betting that Metri Bio's deep scientific roots and focus on a high-unmet-need area can de-risk the early stages of the journey. The company's economic model is predicated on the value of a novel drug candidate, which, if successful, could command significant partnership deals or acquisition interest from larger pharmaceutical companies.
Navigating a field of biological complexity
The ambition is clear, but the path is fraught with the standard challenges of early-stage drug discovery, compounded by the particular mysteries of endometriosis. The most credible near-term risk is that the organoid models, while advanced, may not fully capture the systemic and inflammatory nature of the disease in a living patient. Drug candidates that look promising in a dish can fail for a multitude of reasons in the complex human body.
Metri Bio's most plausible answer to this is the provenance of its science. The models are not a generic off-the-shelf tool, but are built on peer-reviewed, disease-specific research from a leading clinical academic center. The company's strategy appears to be one of depth over breadth, focusing its initial platform on the disease its founders know best. The next twelve months will be a critical proof-of-concept period, where the company must translate its academic validation into proprietary intellectual property,identifying novel targets or compounds that merit further investment.
A key milestone to watch will be the company's first major publication or presentation of data derived from its drug discovery efforts. Peer-reviewed validation of its approach using its own platform would be a strong signal of technical progress to both the scientific community and potential future investors.
The patient perspective and standard of care
For the millions of women with endometriosis, the standard of care today is a difficult reality. First-line treatment typically involves hormonal therapies like birth control pills or gonadotropin-releasing hormone agonists, which aim to suppress ovulation and estrogen production to slow endometrial tissue growth. These treatments can manage symptoms for some, but they are not curative and come with side effects that many find intolerable. When medications fail, the next option is often laparoscopic surgery to excise or ablate the lesions, a procedure that can provide relief but carries surgical risks and a high rate of recurrence.
This cycle of hormonal management and repeat surgery underscores the profound need for new therapeutic options that address the root biology of the disease. Metri Bio's work, still in its earliest stages, represents one of several avenues of research aiming to break that cycle. Its success would be measured not in platform subscriptions, but in whether it can deliver a molecule that makes it to clinical trials and, ultimately, changes the treatment paradigm for this chronic and often debilitating condition.
Sources
- [Metri Bio, June 2024] Metri Bio raises $5M pre-seed round | https://metri.bio/
- [Pace Ventures, 2025] Why We Invested in Metri Bio | https://paceventures.com/articles/why-we-invested-in-metri-bio
- [Fertility and Sterility, 2024] Publication on 3D spheroid generation system for endometrial modeling | 122: e365
- [Fundable, 2025] Metri Bio company description | https://www.tryfundable.ai/company/metri-bio
- [HealthyWomen, 2025] Ashley Abel of Metri Bio Wants to End Endometriosis | https://www.healthywomen.org/condition/ashley-abel-of-metri-bio-wants-to-end-endometriosis
- [Forbes, 2026] Ashley Abel - Forbes 30 Under 30 | https://www.forbes.com/profile/ashley-abel/
- [LinkedIn, 2026] Kathy Potts profile | https://www.linkedin.com/in/kathy-potts-PhD
- [Femtech Insider, 2025] Metri Bio Raises $5M Pre-Seed | https://femtechinsider.com/metri-bio-raises-5m-pre-seed-to-develop-endometriosis-therapeutics/
- [Founder Lodge, Dec 2025] Metri Bio funding round details | https://founderlodge.com/round/Metri-Bio-raises-5000000-Pre-Seed-2025-12-03-Ashley-Abel-PhD-MjQ4Njg